Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2020 · New England Journal of Medicine · 6,783 citations
https://doi.org/10.1056/nejmoa1915745
M
Masatoshi Kudo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2.8K
Papers
124.9K
Citations
143
h-index
1050
i10-index
Masatoshi Kudo is an academic researcher from Kindai University. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Pancreatic and Hepatic Oncology Research. The author has an h-index of 143, co-authored 2403 publications.
ORCID: 0000-0002-4102-3474Papers by this author
worksLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
2018 · The Lancet · 5,257 citations
https://doi.org/10.1016/s0140-6736(18)30207-1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2016 · The Lancet · 3,590 citations
https://doi.org/10.1016/s0140-6736(16)32453-9
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
2017 · Hepatology International · 2,117 citations
https://doi.org/10.1007/s12072-017-9799-9
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 1,625 citations
https://doi.org/10.1016/s1470-2045(18)30937-9
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
2015 · Liver International · 1,218 citations
https://doi.org/10.1111/liv.12818
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat